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Abstract
Stress can cause or contribute to bladder dysfunction though specific effects
remain unclear. Individuals with interstitial cystitis (IC)/bladder pain syndrome
(BPS) experience increased symptom severity with stress, including pain and
increased urgency and frequency of voiding. Further research can identify stressrelated changes to urinary mechanisms, such as changes in sensory
neurotransmitters and subsequent receptor expression. These factors could then
become targets for future therapies providing bladder dysfunction relief. Alterations
in PACAP and TRPV channel expression have been shown in sensory pathways in
response to disease. My research studied the effects of chronic stress on bladder
function and the potential for PACAP(6-38), a PACAP antagonist, to recover normal
function. Mice went through a repeated variate stress regime followed by bladder
tube implant and cystometrogram recording. Bladder, dorsal root ganglia (DRG),
and spinal cord tissues were collected and immunostained for the presence of
TRPV1, TRPV4, and PACAP expression. Chronic stress decreased inter-contraction
interval (ICI) and bladder capacity while increasing bladder pressures. Both control
and stressed male and female mice showed improvement following a 30-minute
intravesical infusion of PACAP(6-38), with ICI and bladder capacity measures
having the most consistent improvement across groups. PACAP and TRPV1
expression was upregulated in the bladder afferent pathway. These findings suggest
that chronic stress can contribute to bladder dysfunction, and it seems to be
mediated in part by upregulation of PACAP and TRPV channel activity. With further
research, these factors may be valid molecular targets for therapy. As chronic stress
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may present alone or in combination with other conditions (IC/BPS, injury, etc.), it
is critical to understand stress-related changes in order to reduce or eliminate their
impact.
Introduction
Normal bladder function is usually unappreciated until something goes
wrong. An estimated 3.3 to 7.8 million adult females in the U.S. alone suffer
symptoms of IC/BPS (Berry et al., 2011). IC/BPS is a debilitating inflammatory
disease that impedes daily activities and makes participating in the community
difficult through persistent discomfort and bladder dysfunction (Beckett et al.,
2014). Chronic stress, related or unrelated to the disease, may exacerbate symptoms
and thus reduce quality of life further (Robbins et al., 2007; Rothrock et al., 2001).
Additionally, chronic stress, as an inflammatory condition, may be able to
independently cause bladder dysfunction with a presentation similar to IC/BPS
(Smith et al., 2011). Currently, the mechanisms by which stress contributes to
bladder dysfunction are unknown, and there is no cure besides removing the
stressor(s), which is not always possible. Also, there is no cure for IC/BPS. This
research is intended to make progress towards these goals.
The Basics of Bladder Innervation
The bladder is composed of four layers – an inner endothelial layer of
epithelium, the lamina propria (connective tissue and vasculature), the detrusor
smooth muscle, and the perivesical soft tissue (fat and vasculature). The inferior
aspect of the bladder is the bladder neck, containing the more superior internal
sphincter (smooth muscle) and the external urethral sphincter (striated muscle).
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These components all work together to achieve two modes of operation: storage
and elimination.
Normal urinary bladder function is a consistent, repetitive cycle of storage
and voiding (micturition) controlled by conscious and autonomic inputs (de Groat et
al., 1993). In a mature urinary system, bladder filling occurs with somatic and
sympathetic contraction of the sphincter muscles and sympathetic inhibition of
detrusor smooth muscle activity (de Groat & Booth, 1980). Sensory nerves relay
information about fullness from the bladder to the spinal cord, where there are
localized reflex pathways that also project to the pontine micturition center and
cerebral cortex (Mahony et al., 1977; Zhang et al., 2005). Parasympathetic
innervation contracts the detrusor muscle whereas sympathetic and somatic
innervation relaxes the sphincter muscles, which together allows for voiding
(Edvardsen, 1972; Mahony et al., 1977).
Changes in these pathways produce voiding dysfunctions because neural
control as well as detrusor muscle activity is often altered. This presents as changes
(often increases) in voiding frequency, nocturia, urgency, incomplete emptying,
urinary hesitancy, and suprapubic pain (Irwin et al., 2006; Koziol et al., 1993). These
changes are studied functionally by measuring bladder capacity, ICI (the time
between voids), and pressure values throughout a micturition cycle (Maggi et al.,
1986; Schafer et al., 2002). Pressures are lowest right after voiding when the
bladder is empty. Pressure remains steady throughout the filling phase until it
dramatically increases just prior to voiding (Maggi et al., 1986). Unstable or
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consistently elevated pressures throughout a micturition cycle suggest dysfunction
(Malmgren, 1987; Neal et al., 1987).
States of urinary bladder dysfunction are usually caused by changes to
autonomic control of the system (as opposed to conscious inputs). This can happen
through changes in perceived bladder sensations, which occurs when expression of
sensory molecules and their channels are altered in the bladder afferent relay. For
example, two channels in the transient receptor potential (TRP) superfamily,
transient receptor potential vanilloid family member 1 (TRPV1) and member 4
(TRPV4), are important in maintaining proper bladder sensation and activity, and
have increased expression levels in IC/BPS (Everaerts et al., 2010; Wang et al.,
2008). As such, studying these channels in their relation to bladder dysfunction has
lead to a better understanding of IC/BPS physiology and potential treatments.
Relative location and density of these channels indicate specific functional
contributions in supporting normal voiding behavior (Yamada et al., 2009).
TRPV1
TRPV1 channels are temperature-sensitive and respond to a variety of
sensory molecules that will transmit nociception, including nerve growth factor
(NGF), bradykinin, and capsaicin (Chuang et al., 2001). These channels are
expressed in afferent nerves that relay information on bladder distension and
chemical irritation from the urinary bladder (Yamada et al., 2009). Activation of
these channels causes perceived pain, bladder hypersensitivity, and compromised
bladder function. Birder and colleagues (2001) found TRPV1 channels in the
urothelium cells as well. TRPV1(-/-) mice have more non-voiding bladder

6
contractions than control mice and a loss of unconscious reflexive voiding (Birder et
al., 2002). This suggests a role for TRPV1 in normal bladder function, as there is
dysfunction present without it. Desensitizing TRPV1 channels using capsaicin did
not impact ICI in these mice, though it did have a negative effect on ICI in controls
(Birder et al., 2002). These results suggest that the TRPV1 is important in detecting
irritants like capsaicin and amplifying the signal as it travels towards spinal and
brain centers to evoke a response. This indicates that TRPV1 acts in a
physiologically relevant manner in bladder afferents.
TRPV4
Previous studies have indicated that TRPV4 channels may function as a
sensor of mechanical pressure in the bladder. Extensive TRPV4 expression has been
found in the urothelium (Yamada et al., 2009). Alessandri-Haber and colleagues
(2003) demonstrated that TRPV4 acts on primary afferent nerve fibers in response
to changes in osmolarity and/or mechanical stretch. It seems that these fibers are
mechanosensitive but capsaicin-insensitive nociceptive (pain) fibers (Aizawa et al.,
2011). Activation of TRPV4 caused pain-related behavior in rats, supporting the idea
that the channel is involved in sensory transmission (Alessandri-Haber et al., 2003).
These behaviors were not seen in TRPV4 knockout mouse models (AlessandriHaber et al., 2003). This suggests that TRPV4 signaling is required for hypotonicrelated nociception. Guler and colleagues (2002) also found that TRPV4 channels
are activated in response to warm temperatures, with increased sensitivity to heat
responses in hypo-osmotic solutions. This suggests that TRPV4 could be a
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multimodal receptor, responding to and integrating at least two types of sensory
information.
The functional significance of TRPV4 has not been fully elucidated, but clear
behavior changes have been found. Mice without TRPV4 channels in the urinary
bladder have fewer voiding contractions (Gevaert et al., 2007). Similarly, research
by Everaerts and colleagues (2010) has also shown difficulty in producing high
cystitis-like voiding frequencies in mice TRPV4 (-/-) mice. Merrill and colleagues
(2012) found increased expression levels of TRPV4 in chronic cystitis. Similar
bladder function changes have been seen with stress models. Merrill & Vizzard
(2014) found increased TRPV4 expression in the urinary bladder following stress.
Similar results occurred in control mice with TRPV4 agonist administration,
suggesting that increased TRPV4 expression may contribute to bladder dysfunction
(Merrill & Vizzard, 2014). These decreases in bladder capacity with increases in
TRPV4 expression suggest that this channel has an important mechanosensor role
in normal bladder function.
In control and cystitis-model mice, TRPV4 antagonist action increases
bladder capacity and reduces ICI (Thorneloe et al., 2008). There was also an
improvement in bladder capacity and ICI following TRPV4 antagonist
administration in stressed animal models (Merrill & Vizzard, 2014). By detecting
changes in bladder wall stretch, these receptors signal apparent bladder fullness.
These results suggest the involvement of TRPV4 in normal bladder function, as well
as a possible role in the response to stress and cystitis.
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Pituitary adenylate cyclase-activating polypeptide (PACAP)
PACAP-38, first isolated by Miyata and colleagues (1989), is a well-conserved
sensory neurotransmitter in mammals with a widespread presence throughout the
central and peripheral nervous systems. Dun and colleagues (1996) found PACAPimmunoreactivity (PACAP-IR) in the dorsal horn of the spinal cord, with light
expression in ventral horn. A distribution primarily in the dorsal horn suggests
involvement in sensory and autonomic activity. With administration of capsaicin,
the number and intensity of PACAP-IR nerve fibers were reduced in the lower
urinary tract (LUT; comprised of the bladder, urethra, and prostate) (Fahrenkrug &
Hannibal, 1998). This led them to propose that PACAP expression depends on
sensory input. Helyes and colleagues (2007) went on to show that PACAP is released
by capsaicin-sensitive neurons into systemic circulation. This would support the
idea that PACAP does respond to sensory information, as we know that capsaicinresponsive neurons are located in the afferent limb of bladder innervation. This also
suggests co-localization of PACAP with TRPV1 channels in urinary bladder afferents.
Variations in PACAP levels have been shown to cause a variety of functional
changes in the micturition process. PACAP-38 was found to produce relaxation of
the pig urinary bladder neck through PACAP receptor activation and subsequent
inhibitory signaling (Hernandez et al., 2006). The bladder neck is the sphincter
smooth muscle that, when relaxed, allows for voiding. High levels of PACAP may
then prompt repeated relaxations of this muscle that may contribute to high levels
of non-voiding contractions of the detrusor. This effect was diminished with
administration of the antagonist PACAP(6-38) (Hernandez et al., 2006). PACAP (-/-)
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mice show increased bladder capacity, ICI, and void volume (May & Vizzard, 2010).
The detrusor was contracted for significantly longer than controls and there was a
large residual volume (May & Vizzard, 2010). PACAP has been observed in spinal
cord (L1, L2, and L4-S1) and DRG (L1, L2, L6, and S1), with an increase in expression
after chronic cystitis (Vizzard, 2000). This shows further presence in afferent
signaling.
Girard and colleagues (2013) demonstrated an increase in TRPV4 expression
in the lumbosacral (L1, L2, L6-S1) DRGs in transgenic mice with a chronic
overexpression of nerve growth factor (NGF), which regulates PACAP and its
receptors. Mice with chronic overexpression of NGF at the level of the urinary
bladder exhibit significantly increased voiding frequency. This suggests that TRPV4
channel changes may show similarities to changes in PACAP, which aids in detrusor
muscle contraction for voiding. Combined with the understanding that TRPV1 and
PACAP are expressed in capsaicin-sensitive neurons, these factors seem to be coexpressed.
An increase in PACAP expression with cystitis could explain bladder
overactivity. The blockade of PACAP-selective channels using the antagonist
PACAP(6-38) reduces urinary frequency in rats with bladder inflammation induced
by cyclophosphamide (CYP) (Braas et al., 2005). This is supported by research
demonstrating a decrease in bladder overactivity with PACAP(6-38) administration
in rodent models of chronic spinal cord injuries, another inflammatory condition
(Yoshiyama & de Groat, 2008). Because stress can lead to inflammation and
previous cystitis models shown upregulation in PACAP and TRPV channels (Braas et
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al., 2005; Girard et al., 2013; Vizzard, 2000), the expression of both PACAP and TRPV
channels after prolonged stress is expected to be similar to that seen with cystitis.
Previous research has also suggested that PACAP and TRPV channels are both
expressed in small diameter DRG neurons (Helliwell et al., 1998; Moller et al., 1993).
Because of similar function and co-expression, alleviation of stress-related urinary
symptoms may be possible through alterations of these mechanisms. This may
provide insight into possible targets for drugs to help provide relief for voiding
changes seen in inflammatory conditions.
Bladder Function & Stress
Bladder dysfunction reduces quality of life through psychosocial factors,
including financial, social, physical, and emotional stress. Severe symptoms can limit
patients’ confidence to travel far from their homes. IC/BPS has been shown to lead
to increased likelihood of missing or quitting work through collective symptom
impact, depressive symptoms, and co-morbidities (Beckett et al., 2014). These
comorbidities may often be mental health concerns. For example, there is an
increased prevalence of IC/BPS in those diagnosed with anxiety disorders (Clemens,
Brown, & Calhoun, 2008). Life stressors can exacerbate bladder dysfunction.
Rothrock and colleagues (2001) have found that higher levels of stress are related to
increased IC/BPS symptoms.
Although many functional changes in LUT physiology have been implicated
in IC/BPS, stress-related changes to urinary sensory mechanisms are largely
unknown. These physiological changes, however, are very important to understand
and create therapies for stress-related bladder dysfunction. This research will
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include studying changes in the relay of the message via modulation of ion channel
and neuropeptide expression at key locations (e.g., urinary bladder, spinal cord, and
DRG) in the voiding reflex, and advancing this knowledge may eventually contribute
toward providing relief to millions with bladder dysfunction. Following chronic
stress, I hypothesize that there is increased expression and co-expression of TRPV1
and TRPV4 channels with PACAP in the lumbosacral (L1, L2, L6, and S1) DRG. I also
hypothesize that chronic stress will increase voiding frequency and threshold
pressure, which will be alleviated with PACAP(6-38) administration into the urinary
bladder.
Methods
The work was completed in the Vizzard Laboratory in the Given Building and
in the Given Animal Care Facility at the UVM College of Medicine. Dr. Vizzard and
other laboratory members including a senior research technician and postdoctoral
associate were available to provide day-to-day guidance and support. All
experimental protocols involving animals were reviewed and approved by the
Institutional Animal Care and Use Committee of the University of Vermont.
Repeated Variate Stress
PACAP-GFP transgenic mice donated by Dr. James A. Waschek (UCLA) were bred inhouse onto a C57BL/6 background. Adult PACAP-GFP mice (female n=12, male
n=15) were randomly assigned by cage to control or stressed groups. All animals
remained housed as they were before the experiment (single or colony), were
maintained on a 12-hour light/dark cycle, and had access to food and water ad
libitum. Enrichment was prohibited, including huts. The stressed mice underwent
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seven days of repeated variate stress, with one stressor per day as seen in Table 1.
This paradigm works to best resemble life stress, as there are multiple different
sources of stress that change frequently.

Table 1. The schedule and length of stressor
events in the chronic variate stress protocol.
Day

Stressor

Duration

1

Pedestal

30 minutes

2

Swim

5 minutes

3

Foot
Shock

4

Restraint

two at 5 seconds each,
separated by one
minute of rest
1 hour

5

Oscillation 30 minutes

6

Swim

5 minutes

7

Foot
Shock

two at 5 seconds each,
separated by one
minute of rest

Pedestal: Mice were placed on a pedestal platform (7”x7”) three feet from the
ground for thirty minutes. There was one mouse per platform and the two pedestals
were placed in the center of black netting to catch any mice that jump or fall off of
the platform. The platforms were sanitized with an alcohol solution in between mice
to remove urine and fecal pellets.
Swim: Mice were forced to swim individually for five minutes in room temperature
water deep enough that their tails could not touch the bottom of the container.
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Afterward, they were placed in a holding cage with super absorbent bedding for five
minutes before being returned to their home cages.
Foot Shock: Mice were put in a 30 × 25 × 35 cm (L × W × H) Plexiglas conditioning
chamber (Med Associates, St. Albans, VT) to acclimate for five minutes. Then, two
five-second 0.29 mAmp shocks were delivered one minute apart through the
chamber floor. The drop tray was sanitized in between animals to remove urine and
fecal pellets.
Restraint: Mice were placed headfirst into 50mL tubes that were modified such that
the bottom portion was cut off to provide ventilation and a slit towards the top of
the tube allowed the tail to rest more naturally outside of the tube. A rubber plug
with additional ventilation holes was placed into the tubes behind the mouse to
restrict backward motion. Blocks were placed on either end of the tubes so that they
could not roll. Mice remained in the tubes for one hour.
Oscillation: Mice were placed individually into clean and empty standard mouse
housing cages that were placed on a multi-purpose rotator (Fisher Scientific, Morris
Plains, NJ) to oscillate for 30 minutes at slow to medium speed.
Bladder Tube Implant
After seven days of stress, the mice underwent an intravesical catheter
implant. Using 2% isoflurane (3% for stressed animals) as general anesthesia, a
lower midline abdominal incision was made to expose the bladder. Polyethylene
tubing was inserted into the dome of the bladder and secured using a 6-0 nylon
purse-string suture. The sealed distal end was tunneled subcutaneously to the back
of the neck to remain in the subcutaneous space during recovery. The abdominal
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incision was closed with a chromic gut suture through the abdominal muscle and
then a 4-0 nylon running stitch externally. The neck incision was closed with 4-0
nylon stitch and both incision sites were covered with GLUture. Buprenorphine
(0.03 μl dose of .05 mg/ml) and carprofen (0.01 ml/g dose of 0.05 mg/ml)
administered subcutaneously were given as analgesics prior to surgery and for 72
hours post-operatively.
Tube Externalization
After the recovery period, the mice were anesthetized with isoflurane (2%)
to exteriorize the distal end of the tubing for cystometry. The stitches in the back of
the neck were removed, the extra length of tubing was removed from the
subcutaneous space, and the neck was resealed with GLUture. Tape was used to
cover the externalized tubing to prevent any chewing damage.
Bladder function evaluation with cystometry
The mice were placed unrestrained in a cystometry recording cage with a
wire floor. The tubing was connected to a pressure transducer port, which was
connected to a syringe pump that infused saline at a constant rate (25 μl/min) to
produce repetitive bladder contractions. Measuring began after a 15-minute
anesthesia recovery period and acclimation time. A pan on a balance placed below
the cage was used to catch and measure urine output. The minimum pressure, fill
pressure, voiding threshold pressure, maximal voiding pressure, ICI, bladder
capacity, and void volume was recorded by a small Animal Cystometry System (Med
Associates, St. Albans, VT). Bladder capacity was measured as the infused volume
between micturitions. To measure the effects of a PACAP blockade, the mice were
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given a continuous 300 nM infusion of PACAP(6-38), a PAC1 receptor antagonist, for
thirty minutes. This was done by first disconnecting the mouse’s tubing, removing
remaining saline from the tubing, filling with PACAP antagonist solution, and then
reconnecting the tubing and restarting the infusion pump. Following this period, the
line was again flushed to remove remaining antagonist before a second round of
recording with the saline infusion.
Tissue Collection & Preparation
The mice were euthanized via isoflurane (5%) and thoracotomy. The brain,
spinal cord, DRG, and bladder were removed. Detrusor and urothelium layers were
separated from each other. Tissues were placed in a 4% paraformaldehyde solution
in a phosphate buffered saline (PBS) solution overnight, which was replaced by a
30% sucrose solution in PBS for the following week. Detrusor and urothelium were
cross-sectioned through the longer plane using surgical scissors. The other tissues
were embedded in an OCT compound within a cryomold cassette for sectioning. The
tissue was sectioned using a cryostat and mounted onto slides (DRG, 10μm) or freefloated in wells (brain and spinal cord sections, 40μm).
Immunohistochemistry
Immunohistochemistry using anti-TRPV4-ATTO-550 (#ACC-034-AO,
Alomone Labs, Jerusalem, Israel) and VR1 primary antibody (R-130, Santa Cruz,
Santa Cruz, CA) was used to determine the expression of TRPV1 and TRPV4
channels. Species-specific secondary antibodies tagged with fluorophores distinct
from GFP were used to label both TRPV1 and TRPV4. Antibody specificity was
previously demonstrated using DRG and spinal cord tissue harvested from TRPV1
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and TRPV4 null mice. In tissues from TRPV1 and TRPV4 null mice, no TRPV1- or
TRPV4-immunoreactivity, respectively, was demonstrated. Additionally, the
transgenic mice (PACAP-GFP) are designed to exhibit green fluorescent protein
(GFP) expression at sites with PACAP expression. Then the slides were viewed with
a fluorescence microscope to determine the location and expression density of the
TRPV channels of interest. Optical density and co-expression software with confocal
microscopy were used to quantify expression, changes in expression and coexpression of TRPV channels and PACAP.
Statistical Analyses
All values represent means ± SE. Cystometry data were compared using
paired t-tests and ANOVA, with each animal serving as its own control.
Immunohistochemical data were compared with independent t-tests. Statistics were
run using SPSS software obtained through The University of Vermont.
Results
Bladder Function
Generally, a healthy bladder results in relatively high bladder capacity with
low pressure and therefore relatively long inter-micturition intervals. All bladder
pressure values should be relatively low, with the peak micturition pressure having
the highest value.
Females.

There was no significant difference between control and stressed

functional values before PACAP(6-38) infusion. Both control and stressed female
groups saw improvement on all functional measures after infusion. Control mice
saw significant improvement post-infusion on ICI measures (t(5) = 3.461, p ≤ 0.05)
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and bladder capacity (t(5) = 3.466, p ≤ 0.05) (Fig. 1 & 2). Threshold, minimum, fill,
and maximum pressures all decreased post-infusion but not significantly (Fig. 3).
The stressed cohort saw significant improvement post-infusion on ICI measures (p ≤
0.05) and bladder capacity (p ≤ 0.05) (Fig. 4 & 5). While all pressure measures did
decrease post-infusion, no changes were significant (Fig. 6).
Males.

There were no significant differences between control and stressed

functional values before PACAP(6-38) infusion. Both control and stressed male
groups saw improvement on all functional measures after infusion. Control mice
had non-significant increases in ICI and bladder capacity (Fig. 7 & 8) and decreases
in all pressure values (Fig. 9). Stressed mice had significant increases in ICI (t(6) =
4.312, p ≤ 0.01) and bladder capacity (t(6) = 4.310, p ≤ 0.01) (Fig. 10 & 11). All four
pressure values were decreased, with minimum pressure (t(6) = 3.065, p ≤ 0.05)
and fill pressure (t(5) = 2.452, p ≤ 0.05) being significantly so (Fig. 12).
Histology
In the DRG, there was increased expression of TRPV1-IR and PACAP-IR cells
in the stressed mice (Fig. 12 & 13). These increases were significant at the L1 (p ≤
0.001), L2 (p ≤ 0.01), L6 (p ≤ 0.01), and S1 (p ≤ 0.001) levels. PACAP-IR was also
increased under stress conditions at all levels of the DRG, with significant increases
at L1 (p ≤ 0.001), L5 (p ≤ 0.05), and S1 (p ≤ 0.05). The number of cells expressing
both TRPV1-IR and PACAP-IR was similar between stressed and control samples at
all levels of the DRG.
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Discussion
Bladder Function
The repeated variate stress regime decreased ICI and bladder capacity while
increasing bladder pressures in both male and female mice. This presentation is
remarkably similar to that seen in animal models of IC/BPS. These results suggest
that chronic levels of stress are capable of producing functional changes in the
urinary system. Stress was the only experimental condition in this research, which
suggests that these urinary changes may occur in the absence of other contributing
factors, such as disease. When combined with another condition like IC/BPS or
spinal cord injury, stress could then exacerbate current symptoms or add new
complications.
Intravescial PACAP(6-38) Infusion
PACAP(6-38) was shown to aid urinary bladder function across all
experimental groups. Improvement was seen most consistently in ICI and bladder
capacity values, with female control, female stressed, and male stressed cohorts
showing significant improvement. This provides supporting evidence to target
PACAP for symptom relief.
Female stressed and control mice showed better functional values after
PACAP(6-38) infusion. Neither group showed significant changes from their preinfusion values. Because both stressed and controls saw similar levels of functional
improvement, the effect of PACAP(6-38) infusion on bladder function may be
universally beneficial. This would also suggest, then, that the magnitude of effect of
PACAP(6-38) on the urinary bladder is not improved in the presence of stress.
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PACAP(6-38) could be working in a non-specific manner to generally improve the
function of the bladder without addressing the specific mechanism(s) altered by
stress. Brass and colleagues (2005) have found evidence for PACAP(6-38) in cystitis
symptom alleviation. This provides support for a positive effect on inflammatory
states, despite the method of impact.
This equal improvement in both experimental groups was not the case in the
male mice. While all functional values of stressed and control male mice improved
with infusion, stressed mice showed more improvement than controls. This was
seen in the significant decreases in minimum and fill pressures for stressed mice
post-infusion. This would suggest that stress might increase the magnitude of effect
for this therapy, whether it is caused by an increase in general health of the system
or by improvement of a stress-specific mechanism.
Additionally, both theories may be right and there may be sex differences in
urinary innervation, control, and response to stress. Overall, these sex differences in
response to therapy may also suggest that the PACAP(6-38) infusion is having sexdependent effects on bladder function. This could be the result of differing
mechanisms of bladder innervation or varying levels of contribution the PACAP
mechanisms may have on overall function.
Mouse estrous cycles were not controlled for in this experiment, which could
be a confounding variable in the female response to stress. Other experiments on
bladder function have made efforts to control for estrous cycles (Wang et al., 2008).
Shea and colleagues (2000) have suggested that sensory innervation to the bladder
could be sensitive to hormonal status, especially mechanoreceptive input. Johnson
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and Berkley (2002) found that threshold pressure of inflamed bladders, but not
normal bladders, was influenced by estrous state. This could be a direct result of
hormones or, more likely, the interaction between hormones and sensory
neurotransmitters. This could contribute to the increased variability seen in female
mice groups, and should be taken into consideration with housing style and timing
of future experiments.
Neither of the stressed groups was significantly worse in baseline functional
values when compared to their control counterparts. This may raise questions to the
validity of the repeated variate stress regime and if the stressed cohorts were
actually stressed to a substantial degree to be considered a good model for chronic
stress. However, functional values for stressed groups were on average worse than
controls before administration of PACAP(6-38). All values trended in the expected
direction under stress despite significance. These animals were also visibly stressed,
as seen by anxiety-like behaviors including increased startle, frequent
urination/defecation, and hair loss. These behaviors were not measured.
Further measures like blood cortisol levels could be taken to determine
stress level. Preliminary cortisol measurements done in new groups of male control
(n=4) and stressed (n=5) and female control (n=5) and stressed mice (n=5) showed
that stressed groups had higher average cortisol levels than control groups. Neither
female (p = .102) nor male (p = .068) was significantly above the control condition.
Being that this is preliminary testing, a larger sample size could lead to significance
and a stronger argument for substantial stress under the repeated variate stress
regime.
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Histology
The stressed male mice saw significantly increased rates of both PACAP- and
TRPV1-IR cells in the DRG. This would support the theory that PACAP is a sensory
neurotransmitter that participates in the relay of sensory information, especially
nociception. The increase in expression suggests that more noxious input is sent to
CNS control centers, contributing to higher levels of reflexive urge to
urinate/bladder contractions and perceived pain or discomfort. This, then, could
account for accommodating changes in bladder function in an attempt to react to
this abnormal sensory information. It could also explain the increased awareness of
the urinary bladder state (notably pain), resulting in psychological symptom
development. Therapies targeting PACAP, then, are targeting the afferent branch of
this loop, reducing information transmission before it reaches the central relay
centers.
PACAP-IR cells in the bladder provide support for the presence of this
powerful substrate in peripheral tissue, with physiological functions in the
immediate area. PACAP may also have an immediate effect on release, as it has been
shown before to act in a localized manner on smooth muscle inhibition and indirect
excitation (Fox-Threlkeld et al., 1999). The location and function of the detrusor
smooth muscle in bladder reflexology lends itself as a possible target for PACAP
upregulation.
Future Directions
This work should be continued in an effort to fully describe the effect of
chronic stress on the body. Further research on both sexes with control for estrous
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cycle will help to determine the real differences in control and organization of the
urinary bladder innervation that may lead to varying presentations of stress and
responses to therapeutics. It is unclear what factor of urinary control and output
may be causing these apparent sex differences in this experiment.
PACAP(6-38) infusion improved bladder function overall and therefore
PACAP receptors may be a valid target for therapy for those with bladder
dysfunction caused or exacerbated by stress. Because chronic stress presents with
symptoms similar to other conditions, notably cystitis, PACAP(6-38) administration
should be evaluated in other bladder dysfunction states.
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Figure 2. Average maximum infused
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mice during voiding contractions.
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Figure 4. Average inter-micturition
interval for female stressed PACAP-GFP
mice during voiding contractions.
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Figure 5. Average maximum infused
volume (bladder capacity) into female
stressed PACAP-GFP mice during
voiding contractions.
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Figure 3. Urinary bladder pressures in control
female PACAP-GFP mice throughout the
micturition cycle.
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Figure 6. Urinary bladder pressures in stressed
female PACAP-GFP mice throughout the
micturition cycle.
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Figure 8. Average maximum infused
volume (bladder capacity) for control
male PACAP-GFP mice during voiding
contractions.
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Figure 7. Average inter-micturition
interval for control male PACAP-GFP
mice during voiding contractions.
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Figure 10. Average inter-micturition
interval for stressed male PACAP-GFP
mice during voiding contractions.
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Figure 11. Average maximum infused
volume (bladder capacity) for stressed
male PACAP-GFP mice during voiding
contractions.
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Figure 9. Urinary bladder pressures in control male
PACAP-GFP mice throughout the micturition cycle.
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Figure 12. TRPV- and PACAP-IR in DRG
sections at the L1 level of a stressed
mouse.

Figure 13. TRPV- and PACAP-IR in DRG sections at
the L6 level of stressed mouse.
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